Grace Therapeutics, Inc. financial data

Symbol
GRCE on Nasdaq
Location
Princeton, NJ
Fiscal year end
31 March
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 971% % -3%
Debt-to-equity 10% % -43%
Return On Equity -13% % 34%
Return On Assets -12% % 29%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 15,474,026 shares 53%
Common Stock, Shares, Outstanding 14,128,562 shares
Entity Public Float $24,040,390 USD 36%
Weighted Average Number of Shares Outstanding, Basic 15,924,522 shares 38%
Weighted Average Number of Shares Outstanding, Diluted 15,924,522 shares 38%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $5,350,000 USD -39%
Selling and Marketing Expense $252,000 USD -62%
General and Administrative Expense $7,154,000 USD -1.8%
Operating Income (Loss) $12,504,000 USD 22%
Nonoperating Income (Expense) $3,062,000 USD 68%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $9,442,000 USD 34%
Income Tax Expense (Benefit) $1,623,000 USD 39%
Net Income (Loss) Attributable to Parent $7,819,000 USD 33%
Earnings Per Share, Basic 0 USD/shares 43%
Earnings Per Share, Diluted 0 USD/shares 43%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $16,862,000 USD 11%
Accounts Receivable, after Allowance for Credit Loss, Current $398,000 USD -52%
Assets, Current $17,298,000 USD 7.7%
Property, Plant and Equipment, Net $15,000 USD -38%
Operating Lease, Right-of-Use Asset $0 USD -100%
Intangible Assets, Net (Excluding Goodwill) $41,128,000 USD 0%
Goodwill $8,138,000 USD 0%
Assets $66,576,000 USD 1.9%
Employee-related Liabilities, Current $412,000 USD 10%
Accrued Liabilities, Current $814,000 USD -18%
Liabilities, Current $1,245,000 USD -53%
Deferred Income Tax Liabilities, Net $2,312,000 USD -41%
Operating Lease, Liability, Noncurrent $0 USD -100%
Liabilities $3,758,000 USD -59%
Accumulated Other Comprehensive Income (Loss), Net of Tax $6,038,000 USD 0%
Retained Earnings (Accumulated Deficit) $224,987,000 USD -3.6%
Stockholders' Equity Attributable to Parent $62,818,000 USD 12%
Liabilities and Equity $66,576,000 USD 1.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,801,000 USD 50%
Net Cash Provided by (Used in) Financing Activities $327,000 USD
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 100,000,000 shares
Common Stock, Shares, Issued 14,128,562 shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $2,128,000 USD 41%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $16,862,000 USD 11%
Deferred Tax Assets, Valuation Allowance $49,530,000 USD 4.8%
Deferred Tax Assets, Gross $58,779,000 USD 11%
Operating Lease, Liability $0 USD -100%
Depreciation $2,000 USD 100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $7,819,000 USD 33%
Property, Plant and Equipment, Gross $26,000 USD -96%
Operating Lease, Liability, Current $0 USD -100%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Deferred Income Tax Expense (Benefit) $0 USD
Deferred Tax Assets, Operating Loss Carryforwards $43,049,000 USD 5.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares
Additional Paid in Capital $293,842,000 USD 1506%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $9,249,000 USD 58%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares